Capecitabine, DNA/RNA Synthesis Inhibitor

Capecitabine is an oral proagent that is converted to its active metabolite, 5-FU, by thymidine phosphorylase. - Mechanism of Action & Protocol.

Anti-Cancer Drugs-Medicinal Chemistry

Capecitabine induces hand-foot syndrome through elevated thymidine phosphorylase-mediated locoregional toxicity and GSDME-driven pyroptosis that can be relieved by tipiracil

Capecitabine, DNA/RNA Synthesis Inhibitor

Results for DNA Synthesis Abcam: antibodies, proteins, kits

Frontiers Co-delivery of Cisplatin(IV) and Capecitabine as an Effective and Non-toxic Cancer Treatment

Chemotherapy and Transplantation: The Role of Immunosuppression in Malignancy and a Review of Antineoplastic Agents in Solid Organ Transplant Recipients - American Journal of Transplantation

Cellular resistance mechanisms in cancer and the new approaches to overcome resistance mechanisms chemotherapy

Structures and mode of action of antimetabolites and DHFR inhibitors.

Chemotherapeutic agents - Knowledge @ AMBOSS

Full article: DNA synthesis inhibitors for the treatment of gastrointestinal cancer

Gemcitabine (LY 188011), DNA Synthesis Inhibitor

Nucleoside analogues and nucleobases in cancer treatment - The Lancet Oncology